Login / Signup

Valproate-associated foetal malformations-Rates of occurrence, risks in attempted avoidance.

Frank J E VajdaTerence J O'BrienJanet E GrahamAlison A HitchcockCecilie M LanderMervyn J Eadie
Published in: Acta neurologica Scandinavica (2018)
Avoiding valproate intake during pregnancy is likely to reduce the incidence of foetal malformation, but at a cost of worsened maternal epilepsy control. Individualization of treatment is particularly important in considering withdrawal of valproate in the light of the fact that it is much more widely used in generalized epilepsy, there being fewer alternative drugs than for focal epilepsy and withdrawal is not without risk for both mother and baby. This study may provide a quantitative basis for assessing the balance between benefit and disadvantage for individual women with valproate-treated epilepsy who are considering pregnancy.
Keyphrases
  • risk assessment
  • risk factors
  • temporal lobe epilepsy
  • gestational age
  • high resolution
  • pregnant women
  • birth weight
  • climate change
  • body mass index